2024
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia
Liu M, Ren Y, Zhou Z, Yang J, Shi X, Cai Y, Arreola A, Luo W, Fung K, Xu C, Nipp R, Bronze M, Zheng L, Li Y, Houchen C, Zhang Y, Li M. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell 2024, 42: 885-903.e4. PMID: 38608702, PMCID: PMC11162958, DOI: 10.1016/j.ccell.2024.03.009.Peer-Reviewed Original ResearchConceptsPancreatic cancer cachexiaTumor cellsCancer cachexiaTherapeutic targetLimited treatment optionsPancreatic cancer cellsImmune microenvironmentCCL2/CCR2 axisPotential therapeutic targetTreatment optionsMuscle wastingReprogram macrophagesTumorMuscle atrophyCachexiaCancer cellsMacrophagesNon-autonomous activationMuscle remodelingCancerMuscle degradationSecretionCellsMuscleTWEAK
2023
Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis
Mohammed S, Thadathil N, Ohene-Marfo P, Tran A, Van Der Veldt M, Georgescu C, Oh S, Nicklas E, Wang D, Haritha N, Luo W, Janknecht R, Miller B, Wren J, Freeman W, Deepa S. Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis. Molecular Cancer Research 2023, 21: 933-946. PMID: 37204757, PMCID: PMC10472095, DOI: 10.1158/1541-7786.mcr-22-0820.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseProgression of NAFLDHepatocellular carcinomaChronic inflammationLiver fibrosisMale miceMouse modelCholine-deficient high-fat dietFemale wild-type miceOncogenic pathwaysFatty liver diseaseMarkers of inflammationHigh-fat dietLow-fat dietDevelopment of inflammationValid therapeutic targetWild-type miceHepatic inflammationInflammation contributesLiver diseaseWT miceFemale miceSex-specific differencesInflammationTherapeutic targetCombining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice
Hasan M, Chen J, Matye D, Wang H, Luo W, Gu L, Clayton Y, Du Y, Li T. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice. Journal Of Lipid Research 2023, 64: 100340. PMID: 36737039, PMCID: PMC9986646, DOI: 10.1016/j.jlr.2023.100340.Peer-Reviewed Original ResearchConceptsBile acid poolKO miceTherapeutic efficacyHepatobiliary injuryBile acid pool sizeBile acid exposureGut barrier integrityGut barrier functionBile acid metabolismAcid poolBile acid synthesisAcid pool sizeBile acid uptakePortal inflammationPortal fibrosisGut exposureDuctular reactionGSK2330672Therapeutic reductionUrsodeoxycholic acidMuricholic acidAcid exposureASBT inhibitorSevere cholangiopathyBarrier integrity
2017
HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases
Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman D, Bratcher P, King P. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia 2017, 65: 945-963. PMID: 28300326, PMCID: PMC7944581, DOI: 10.1002/glia.23137.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisNeurodegenerative diseasesIL-1βLateral sclerosisALS spinal cordMutant SOD1 micePossible therapeutic targetTranscription factor NF-κBLipopolysaccharide-induced IL-1βFactor NF-κBMolecular signaturesRole of HuRLuciferase reporter studiesActivated microgliaProinflammatory factorsSOD1 miceIL-6Inflammatory pathwaysMicroglial migrationImmune cellsSpinal cordChronic activationMicrogliaNF-κBTherapeutic target